INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $192,897 | -20.2% | 45,929 | +5.8% | 0.00% | – |
| Q2 2023 | $241,799 | +356.2% | 43,411 | +236.8% | 0.00% | – |
| Q1 2022 | $53,000 | -40.4% | 12,890 | -1.3% | 0.00% | – |
| Q4 2021 | $89,000 | -42.9% | 13,064 | -3.0% | 0.00% | – |
| Q3 2021 | $156,000 | -28.4% | 13,462 | +5.3% | 0.00% | – |
| Q2 2021 | $218,000 | – | 12,787 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |